GeNeuro SA (GEM.F)
| Previous Close | 1.3900 |
| Open | 1.3650 |
| Bid | 1.3750 x 40000 |
| Ask | 1.5850 x 40000 |
| Day's Range | 1.3650 - 1.3650 |
| 52 Week Range | 0.8540 - 1.9750 |
| Volume | |
| Avg. Volume | 22 |
| Market Cap | 42.433M |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5900 |
| Earnings Date | May 08, 2024 - May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireGeNeuro Publishes its 2024 Universal Registration Document
GENEVA, Switzerland, May 02, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), publishes its 2023 Universal Registration Document, in English, which has been filed on April 30, 2024 with the "Autorité des Marchés Financiers (AMF)".
Business WireGeNeuro Reports 2023 Full-Year Results and Provides Corporate Update
GENEVA, April 30, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), reported today its full-year results for the year ended December 31, 2023, and provided a corporate update.
Business WireGeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting
GENEVA, March 20, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of March 18, 2024. These included among o
